Corrected: Takeda Makes some Pipeline Cuts, Says Generic Competition Softened Sales over Last Six Months

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year

OSAKA, Japan -- Takeda ( TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook.

Corrected: Takeda makes some pipeline cuts, says generic competition softened sales over last six months

Takeda said Thursday it has ended work on several early- and mid-stage drug candidates, adding that its sales from April to September took a hit from “generic erosion” and “unfavorable” exchange rates. The Japanese drugmaker ...